Rosetta Genomics Expands Molecular Diagnostics Test Menu With Launch Of OncoGxSelect From Admera Health

New NGS-based Assay Increases Number of Genes Examined for Lung Cancer and Other Solid Tumor Types

PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of OncoGxSelect™, a next generation sequencing (NGS)-based test that detects somatic mutations frequently found in cancers and provides actionable results to help guide therapeutic decisions related to targeted cancer therapies.

“The OncoGxSelect™ test adds to the growing number of services we offer, and further establishes Rosetta Genomics as a leader in delivering personalized diagnostic testing.”

OncoGxSelect™ leverages Admera Health’s industry-leading NGS technology and interrogates 12 genes implicated in highly-prevalent lung cancer types: ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET and ROS1. OncoGxSelect™ is a significant upgrade to OncoGxLung as it increases the number of genes examined from 5 to 12, and has the capacity to be used for other tumor types based on important mutations found in various cancers such as thyroid cancer.

OncoGxSelect™ targets the genes included in nationally accepted clinical guidelines for molecular testing, and establishes a much more attractive opportunity with greater potential for favorable reimbursement.

“Lung cancer is one of the most prevalent cancers worldwide. The commercial launch of this advanced test provides a more comprehensive set of actionable information for the oncologists and pathologists we serve, and adds to a comprehensive lung-specific menu that assists in answering the most difficult clinical questions clinicians face when treating these patients,” stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “The OncoGxSelect™ test adds to the growing number of services we offer, and further establishes Rosetta Genomics as a leader in delivering personalized diagnostic testing.”

Guanghui Hu, PhD, President and CEO of Admera, elaborated, “The development of this OncoGxSelect™ panel and our continued relationship with Rosetta Genomics will increase patient access to cutting edge sequencing diagnostics, advancing precision medicine by providing oncologists with a tool to guide targeted therapy treatment decisions.”

About Admera Health

Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company now offers core FISH, IHC and PCR-based testing capabilities and partnerships in Pathology, Oncology and Urology that provide additional content and platforms that complement Rosetta’s microRNA and Next-Gen Sequencing offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of indeterminate thyroid FNA smears, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs. For more information visit www.rosettagx.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects including, but not limited to statements relating to the increased potential of our commercial and reimbursement efforts, and our continuing relationship with Admera constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.